Isofol Medical

AGM Information • Feb 13, 2023

Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 13, 2023

Today on February 13, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its Extraordinary General Meeting at which the following principal resolutions were passed.

Resolution regarding extra dividend

The board of directors' proposal, regarding distribution of an extra dividend to the shareholders with SEK 0.75 per share, corresponding to a total amount of SEK 122,000,000, failed to reach the required voting majority and the resolution was therefore not adopted.

Resolution regarding voluntary liquidation

The board of directors' proposal, regarding voluntary liquidation of the company, failed to reach the required voting majority and the resolution was therefore not adopted.

The chairman of the board of directors Jan Törnell informed that all directors of the board make their place as directors available as a consequence of the proposed liquidation of the company not being approved.

For more information, please contact

Isofol Medical AB (publ) Jan Törnell, chairman of the board of directors E-mail: jan.tornell@innoext.se

Jarl Ulf Jungnelius, M.D., CEO Email: jungnelius@isofolmedical.com Phone: +46 (0)709-16 89 55

The information was submitted for publication, through the agency of the contact persons set out above, at 17.00 CET on February 13, 2023.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical-stage biotechnology company that has focused its operations on developing and improving the current standard treatment for patients suffering from cancer by increasing treatment efficacy through the use of cytostatics. Isofol's ambition was to develop a drug for first-line treatment of advanced colorectal cancer (mCRC), thereby seeking to improve the current clinical practice by realizing the full strength of 5-FU with the addition of arfolitixorin. Isofol has an exclusive global licensing agreement with Merck & Cie in Schaffhausen, Switzerland, to develop and commercialize arfolitixorin in oncology. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com